IMMUNITYBIO, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
IMMUNITYBIO, INC. (IBRX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $78.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-23
- IMMUNITYBIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $78.70M, a 38.85% decline from fiscal 2024.
- IMMUNITYBIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $128.70M, a 17.82% decline from fiscal 2023.
- IMMUNITYBIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $156.60M, a 34.31% increase from fiscal 2022.
- IMMUNITYBIO, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $116.60M, a 2.55% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $78.70M 10-K · filed 2026-02-23 | |
| 2024-12-31 | $128.70M 10-K · filed 2026-02-23 | |
| 2023-12-31 | $156.60M 10-K · filed 2025-03-03 | -$156.60M 10-K · filed 2024-03-19 |
| 2022-12-31 | $116.60M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $113.70M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $63.40M 10-K · filed 2022-03-01 | $29.70M 10-K · filed 2021-03-04 |
| 2019-12-31 | $18.80M 8-K/A · filed 2021-04-22 | -$53.00M 10-K · filed 2020-03-25 |
| 2018-12-31 | $25.80M 10-K · filed 2019-03-13 | |
| 2017-12-31 | -$8.30M 10-K · filed 2018-03-12 | |
| 2016-12-31 | $58.20M 10-K · filed 2017-03-15 | |
| 2015-12-31 | $69.00M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |